Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

D0600000

Deslanoside

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Deacetyllanatoside C, Desacetyllanatoside C

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C47H74O19
Número CAS:
17598-65-1
Peso molecular:
943.08
Número MDL:
MFCD00135818
Código UNSPSC:
41116107
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

deslanoside

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O1CC(=CC1=O)[C@@H]2[C@@]3([C@@]([C@H]4[C@@H]([C@@]5([C@@H](C[C@H](CC5)O[C@@H]6O[C@@H]([C@H]([C@H](C6)O)O[C@@H]7O[C@@H]([C@H]([C@H](C7)O)O[C@@H]8O[C@@H]([C@H]([C@H](C8)O)O[C@@H]9O[C@@H]([C@H]([C@@H]([C@H]9O)O)O)CO)C)C)C)CC4)C)C[C@H]3O)(CC2)O)C

InChI

1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1

chave InChI

OBATZBGFDSVCJD-LALPQLPRSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Deslanoside EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

Pictogramas

Skull and crossbonesHealth hazard
GHS06,GHS08

Palavra indicadora

Danger

Frases de perigo

H301 + H331,H373

Classificações de perigo

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - STOT RE 2

Código de classe de armazenamento

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Topochemical examinations of the lungs of the rat after combined administration of serpasil and deslanatoside. I. Histochemical examinations.
E A Jedrzejewska
Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina, 42, 133-138 (1987-01-01)
A Fronczak et al.
Polish journal of pharmacology and pharmacy, 41(6), 597-609 (1989-11-01)
4'-epidoxorubicin (4'-epiDXR) was compared with doxorubicin (DXR) for myocardial effects in rabbits. Histologically, both drugs when given for six weeks induced a high incidence of diffused myocardial damage. The myocardial damage was less evident in rabbits treated with 4'-epiDXR than
E J Eichhorn et al.
Circulation, 85(6), 2132-2139 (1992-06-01)
Although changes in contractility are often accompanied by changes in relaxation, a mathematical model of ventricular coupling has not been described. A model we examined suggests a hyperbolic relation between measurements of contraction and relaxation. We thus tested the hypothesis
[Pharmacological cardioversion of paroxysmal atrial fibrillation: 3 methods compared].
D Tsialtas et al.
La Clinica terapeutica, 122(2), 93-98 (1987-07-31)
Wayne L Miller et al.
European journal of heart failure, 4(1), 63-72 (2002-01-29)
Digitalis has a long history in the treatment of heart failure but its effects on cardiac hemodynamics and neurohormonal modulation are not well characterized. The purpose of this study was to evaluate the relationship between atrial natriuretic peptide (ANP) and
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica